(HealthDay News) — A urine-based test could potentially help patients safely avoid unnecessary prostate cancer biopsies, according to a study published online in The Journal of Urology.

Jeffrey J. Tosoian, MD, MPH, from the University of Michigan in Ann Arbor, and colleagues validated an optimal MyProstateScore threshold for clinical use in ruling out grade group ≥2 cancer in men referred for biopsy for possible prostate cancer. The analysis included validation cohorts consisting of 977 men from academic centers and 548 from community settings.

The researchers found that overall, 338 men (22%) had grade group ≥2 cancer on biopsy. A threshold of 10 on the MyProstateScore showed 97% sensitivity and 98% negative predictive value for grade group ≥2 cancer. It is estimated that 387 unnecessary biopsies could have been prevented with MyProstateScore testing (33%), while missing only 10 grade group ≥2 cancers (3.0 percent). MyProstateScore ≤10 provided 96% sensitivity and 97% negative predictive value among 1242 men meeting guideline-based criteria, preventing 32% of unnecessary biopsies and missing 3.7% of grade group ≥2 cancers.


Continue Reading

“The data show that this straightforward, secondary testing approach could reduce the use of more costly and invasive procedures following a prostate-specific antigen test,” Tosoian said in a statement.

Several authors disclosed financial ties to various health care companies.

Reference

Tosoian JJ, Trock BJ, Morgan TM, et al. Use of the MyProstateScore test to rule out clinically significant cancer: validation of a straightforward clinical testing approach. J Urol.